Physiological and QoL Benefits of Qi-Gong in Post-acute Sequelae of Covid-19
Launched by POCHIWU · Mar 12, 2025
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether practicing Qi-Gong, a gentle form of exercise that combines movement, meditation, and breathing, can help improve the physical health and overall quality of life for people experiencing long-term effects after having COVID-19, known as post-acute sequelae of SARS-CoV-2 infection (PASC). The researchers want to see if doing Qi-Gong three times a week for three months can make a difference compared to standard care.
To participate in the trial, you need to be over 20 years old and diagnosed with PASC. It's important to note that people who have difficulty cooperating or have severe schizophrenia cannot take part in this study. If you join, you’ll practice Qi-Gong regularly and keep track of your health data each month. The trial is currently recruiting participants, and everyone, regardless of gender, is welcome to apply. This study could be a great opportunity for those looking to improve their well-being after battling COVID-19.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • PASC
- • above 20 y/o
- Exclusion Criteria:
- • Those who cannot cooperate
- • Severe schizophrenia
About Pochiwu
Pochiwu is a pioneering clinical trial sponsor dedicated to advancing healthcare through innovative research and development. With a focus on enhancing patient outcomes, Pochiwu specializes in conducting cutting-edge clinical trials across diverse therapeutic areas. The organization emphasizes collaboration with healthcare professionals, regulatory bodies, and research institutions to facilitate the efficient progression of new therapies from concept to market. Committed to ethical standards and patient safety, Pochiwu leverages its expertise to contribute to the evolution of medical science and improve the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Taipei City, , Taiwan
Taipei, , Taiwan
Patients applied
Trial Officials
Mei-Hua Wang
Principal Investigator
National Taipei University of Nursing and Health Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported